Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?
Determining Who Benefits Most From Cognitive Rehabilitation for Attention and Memory in Multiple Sclerosis: A Randomised Controlled Feasibility Trial
1 other identifier
interventional
36
1 country
1
Brief Summary
Over the last 20 years, there have been many studies investigating the efficacy of attention and memory rehabilitation for people with multiple sclerosis (MS) however, there appears to be a lack of conclusive evidence regarding the true effectiveness of this intervention. This could be because the participant samples recruited to these studies are often extremely varied in terms of socio-demographics and clinical characteristics, and it would be very unlikely that all people with MS would benefit from these interventions uniformly. Therefore, there is a need to explore which subgroups of people with MS benefit most from cognitive rehabilitation so that this information can be used to help clinicians and services make decisions as to whom this intervention is offered. Cognitive rehabilitation is not routinely provided on the NHS due to lack of resources. This research is important as it will allow these resources to be optimised and made available to those who need them, but also to allow clinicians to understand whether their patient is likely to benefit from cognitive rehabilitation before it is offered. The primary aim of this study is to assess the feasibility and acceptability of undertaking a randomised controlled trial (RCT) to investigate the effectiveness of an online group-based cognitive rehabilitation programme with specific groups of people with MS. The secondary aim is to understand the impact that this intervention may have on various aspects of cognition such as memory, attention, and information processing. This will be assessed through various questionnaires and objective neuropsychological tests. In addition, an algorithm has been developed following the secondary data analysis of a large RCT investigating group-based cognitive rehabilitation for people with MS. This algorithm may be able to determine who benefits most from cognitive rehabilitation, we will therefore use this as part of the data analysis to understand if the algorithm has the potential to be an accurate clinical prediction tool. After completion of the cognitive rehabilitation, a small number of participants in the intervention group will be invited to take part in feedback interviews to give their views on the feasibility and acceptability of the group-based online cognitive rehabilitation and provide any suggestions for improvements for future trials.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable multiple-sclerosis
Started Aug 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 31, 2022
CompletedStudy Start
First participant enrolled
August 15, 2022
CompletedFirst Posted
Study publicly available on registry
August 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2023
CompletedSeptember 9, 2022
September 1, 2022
11 months
May 31, 2022
September 5, 2022
Conditions
Outcome Measures
Primary Outcomes (4)
Acceptability and feasibility of conducting an online group-based cognitive rehabilitation programme.
Feedback interviews will be conducted to understand the acceptability and feasibility of the intervention.
Between the 3-month follow-up point and the 6-month follow-up point, up to 3 months.
Appropriateness of eligibility criteria, baseline and outcome measures, recording of sessions, and randomisation protocol.
Rates of enrolment and drop out will be recorded. Fidelity of the intervention will be assessed by video recording.
From the date of randomisation to date of final follow-up, up to 1 year.
Estimating sample size needed for Phase III RCT.
Sample size calculations will be conducted during the primary analysis.
From the start of the data analysis to study completion date, up to 6 months.
Completion rates of outcome measures.
Based on how many participants complete all of the outcome measures.
6 months.
Secondary Outcomes (10)
Multiple Sclerosis Impact Scale-29
Baseline, 3-months post randomisation, 6-month post randomisation
Everyday Memory Questionnaire-participant.
Baseline, 3-months post randomisation, 6-month post randomisation.
Everyday Memory Questionnaire-relative.
Baseline, 3-months post randomisation, 6-month post randomisation.
General Health Questionnaire-30.
Baseline, 3-months post randomisation, 6-month post randomisation.
Fatigue Severity Scale.
Baseline, 3-months post randomisation, 6-month post randomisation.
- +5 more secondary outcomes
Study Arms (2)
Intervention Group
EXPERIMENTALThis group will receive an online cognitive rehabilitation programme, offered in addition to usual clinical care, to groups of 4-6 participants weekly for 10 sessions.
Usual Clinical Care
NO INTERVENTIONThis group will receive only their usual clinical care, which may include information on cognitive problems as per clinical practice but not specific cognitive rehabilitation.
Interventions
This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
Eligibility Criteria
You may qualify if:
- or over and under 70 years of age.
- Have MS, diagnosed at least 3 months prior to recruitment.
- Have cognitive deficits, defined as performance below the 25th percentile on the Brief Repeatable Battery of Neuropsychological Tests (BRBN).
- Able to speak English sufficiently to complete the cognitive assessments and take part in group sessions.
- Have access to laptop or PC that supports MS Teams.
- Able to give informed consent.
You may not qualify if:
- Vision or hearing problems, such that they are unable to complete the cognitive assessments, judged assessor.
- Have concurrent severe medical or psychiatric conditions which would prevent participants from engaging in treatment, if allocated.
- Are involved in other psychological intervention trials.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Nottinghamlead
- National Multiple Sclerosis Societycollaborator
- University of Lincolncollaborator
Study Sites (1)
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Roshan das Nair, PhD
University of Nottingham
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 31, 2022
First Posted
August 22, 2022
Study Start
August 15, 2022
Primary Completion
July 1, 2023
Study Completion
November 1, 2023
Last Updated
September 9, 2022
Record last verified: 2022-09